Tertiary hyperparathyroidism after long-term phosphate supplementation in adult-onset hypophosphataemic osteomalacia. 1996

J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
Department of Rheumatology, Hospital Príncipes de España, Ciudad Sanitaria, Barcelona, Spain.

We report the development of tertiary hyperparathyrodism in a patient with a sporadic form of adult-onset hypophosphataemic osteomalacia who had been treated with vitamin D or calcitriol and large doses of phosphate. This observation suggests that even with concomitant vitamin D or calcitriol therapy, long-term oral phosphate supplementation may lead to the development of hypercalcaemic hyperparathyrodism. Caution is recommended when relatively large doses of phosphate are used to treat hypophosphataemic osteomalacia of diverse causes.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010018 Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. Adult Rickets,Rickets, Adult
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014807 Vitamin D A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
D017674 Hypophosphatemia A condition of an abnormally low level of PHOSPHATES in the blood. Hypophosphatemias

Related Publications

J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
January 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
April 2000, Journal of endocrinological investigation,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
April 1985, The American journal of medicine,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
February 1995, Clinical endocrinology,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
September 1980, British medical journal,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
January 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
January 1976, The New Zealand medical journal,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
September 2019, Journal of musculoskeletal & neuronal interactions,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
September 1979, Clinica chimica acta; international journal of clinical chemistry,
J Narváez, and J Rodriguez-Moreno, and C Moragues, and E Campoy, and T Clavaguera, and D Roig-Escofet
August 1994, Postgraduate medical journal,
Copied contents to your clipboard!